期刊文献+

胃肠间质瘤的临床诊断分析 被引量:4

Clinical analysis of the diagnosis of gastrointestinal stromal tumors
原文传递
导出
摘要 目的探讨胃肠间质瘤的临床诊断及治疗特点。方法回顾性分析21例胃肠间质瘤患者的临床资料和治疗方法,辅助检查诊断为GIST的方法有:胃镜、肠镜检查及活检组织病理诊断18例(85.7%),增强CT检查12例(57.1%),超声内镜检查8例(38.1%),上消化道造影1例(4.8%)。21例患者均行手术治疗,采用SPSS13.0统计软件进行数据分析,术后免疫组织化学及危险度分级分析比较采用χ2检验,P<0.05被认为有统计学意义。结果 21例中15例为胃间质瘤,6例为小肠间质瘤。本组患者进行CD117、CD34、S100、和SMA等4项免疫组织化学检测,表达阳性率CD117(95.24%)和CD34(71.43%),CD117,CD34在胃肠间质瘤中表达明显高于S100(9.52%)和SMA(38.09%),χ2=10.00、16.13,P<0.05,差异有统计学意义。中、高危患者口服伊马替尼明显提高生存率。结论 CD117与CD34同时表达有助于临床诊断。手术是胃肠间质瘤的主要治疗方法,靶向药物具有延缓胃肠间质瘤的复发和转移的临床意义。 Objective To investigate the clinical characteristics of diagnosis and therapeutic strategies of gastrointestinal stromal tumors ( GISTs ) . Methods Clinical data of 21 patients with GISTs were retrospectively analyzed, including their clinical manifestations , diagnosis and treatment .The auxiliary diagnosis methods of GIST were employed , including gastroscopy , colonoscopy and biopsy tissue pathological diagnosis in 18 patients (85.7%), and enhanced CT examination in 12 patients (57.1%), endoscopic ultrasonography examination in 8 patients (38.1%), and upper gastrointestinal angiography in 1 patient (4.8%).All patients underwent surgery and the final diagnosis was based on postoperative pathology and immunohistochemistry .Clinical data were analyzed by using statistical software SPSS 13.0, the risk of postoperative immunohistochemical and hierarchical analysis by the Chi-square test.A P value 〈0.05 was considered statistically significant . Results Among the 21 patients, 15 had gastric stromal tumors , and 6 had small intestinal stromal tumors CD 117, CD34, S100, and SMA were detected by immunohistochemistry in all 21 patients.The positive expression rates were 95.24%in CD117 and71.43%in CD34 in gastrointestinal stromal tumors, which were significantly higher than 9.52%in S100 and 38.09%in SMA respectively (χ^2 =10.00, 16.13, P〈0.05).The patients with intermediate risk and high risk were treated with imatinib , and their survival rate was significantly improved . Conclusions The simultaneous expressions of CD117 and CD34 are helpful to the clinical diagnosis of stromal stumor .Surgery is the main treatment for GIST , and target drugs for the recurrence and metastasis of the tumor are of clinical significance .
出处 《中华普外科手术学杂志(电子版)》 2015年第4期43-45,共3页 Chinese Journal of Operative Procedures of General Surgery(Electronic Edition)
关键词 胃肠道间质肿瘤 免疫组织化学 诊断 Gastrointestinal stroaml tumors Immunohistochemistry Diagnosis
  • 相关文献

参考文献10

二级参考文献158

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2梁小波,于红宾,王立平.胃肠道间质瘤的临床流行病学调查[J].肿瘤研究与临床,2006,18(8):505-507. 被引量:30
  • 3万德森,伍小军,潘志忠,周志伟,陈功,李力人,卢震海,丁培荣.甲磺酸伊马替尼治疗51例晚期胃肠道间质瘤患者的疗效分析[J].中华医学杂志,2006,86(43):3064-3067. 被引量:15
  • 4杜春燕,师英强.胃肠道间质瘤新辅助治疗进展[J].肿瘤研究与临床,2007,19(1):1-4. 被引量:2
  • 5Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Ter- vahartiala P, Tuveson D, Silberrnan S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
  • 6van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glab- beke M, Silberman S, Nielsen OS. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal strornal turnouts: a phase I study. Lancet 2001; 358:1421-1423.
  • 7Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal strornal tumors. N Engl J Med 2002; 347:472-480.
  • 8Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoom PC, Van Glabbeke M, Bertulli R, Judson I. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-1134.
  • 9DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PWT, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, on behalf of the American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randornised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-1104.
  • 10Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shrnookler B, Sobin LH, Weiss SW. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002; 33:459-465.

共引文献294

同被引文献24

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部